Baseline characteristics of severe asthma patients initiating biologic treatment worldwide

L. Pérez De Llano (Lugo, Spain), A. Cepelis (Singapore, Singapore), T. Tran (Gaithersburg, United States of America), R. Murray (OPRI, Singapore), D. Price (OPRI, Singapore), . Beam Working Group (OPRI, Singapore)

Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Pérez De Llano (Lugo, Spain), A. Cepelis (Singapore, Singapore), T. Tran (Gaithersburg, United States of America), R. Murray (OPRI, Singapore), D. Price (OPRI, Singapore), . Beam Working Group (OPRI, Singapore). Baseline characteristics of severe asthma patients initiating biologic treatment worldwide. 1106

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Identifying patients with severe asthma that will be benefit from biological therapy
Source: Virtual Congress 2020 – Rethinking asthma
Year: 2020


Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma
Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021
Year: 2021



Differences in clinical and inflammatory characteristics between steroid-withdrawal-induced and spontaneous exacerbations in patients with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 199s
Year: 2002

The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma
Source: International Congress 2017 – Bronchial asthma management
Year: 2017


Real-world treatment patterns of newly diagnosed patients with asthma and/or COPD
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021


Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma
Source: Eur Respir J, 52 (4) 1800936; 10.1183/13993003.00936-2018
Year: 2018



The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020

Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008

Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study
Source: International Congress 2017 – Monitoring asthma control
Year: 2017


Associations between clinical, laboratory and therapeutical parameters on admission and adverse outcomes in patients hospitalized for COPD exacerbations
Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management
Year: 2010


Effects of exacerbation risk on symptoms and clinical characteristics in patients with bronchiectasis
Source: Annual Congress 2012 - Assessment of physical activity, exercise, muscle function and clinical characteristics as outcomes in physiotherapy and rehabilitation
Year: 2012

Effect of omalizumab on the risk of hospitalisation in patients with uncontrolled severe asthma in real-life. The PAX-LASER cohort
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


Long-term efficacy of 1 year anti-inflammatory treatment in paediatric patients with mild persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 379s
Year: 2004

Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019

Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019


Spanish consensus on the characteristics of severe asthmatic patients under biological treatment suitable for at home administration
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021


A clinical and outcomes assessment of the management of acute episodes of chronic bronchitis (AECB) : the MOSAIC study - baseline characteristics of screened patients
Source: Eur Respir J 2002; 20: Suppl. 38, 544s
Year: 2002

Clinical characteristics and burden of illness in a cohort of severe asthma patients
Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life
Year: 2016


Clinical characteristics and outcomes in hospitalized COVID-19 patients with COPD
Source: Virtual Congress 2021 – COVID-19 and obstructive diseases: risk factors, management and long-term effects
Year: 2021


Study of clinical presentation and predictors of adverse outcome in patients admitted for acute exacerbation of COPD.
Source: International Congress 2019 – Airway disease-associated exacerbations
Year: 2019